Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Completed 3Terminated 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 36Thoracic 2Head & Neck 2NET 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 70Carcinoma, Neuroendocrine 7Gastro-enteropancreatic neuroendocrine tumor 6Carcinoid Tumor 6Neoplasm Metastasis 5Paraganglioma 3Pancreatic Neoplasms 3Carcinoma, Hepatocellular 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Sarcoma 2Neoplasms 2Lung Neoplasms 2Turcot syndrome 1Triple Negative Breast Neoplasms 1Tertiary Lymphoid Structures 1Teratoma 1Small Intestinal Neuroendocrine Tumor 1Small Cell Lung Carcinoma 1Rectal Neuroendocrine Tumor 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 1Pancreatic Neuroendocrine Tumors in MEN1 1Osteomalacia 1Neuroendocrine Tumors With Metastasis 1Neuroendocrine Tumors Metastatic to the Liver 1Neuroendocrine Tumor Grade 3 1Neuroblastoma 1

Interventions

anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Digestive System Neoplasms × NET × Clear all
NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
150 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡